Lotus Pharmaceuticals, Inc.
Symbol: LTUS
PNK
0.00401
USDTrhová cena dnes
-651.6106
Pomer P/E
-3.8330
Pomer PEG
0.11M
MRK Cap
- 0.00%
Výnos DIV
Lotus Pharmaceuticals, Inc. (LTUS) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.account-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-liab | 0 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 2.7 | 2.7 | 2.9 | |||||||||||
balance-sheet.row.retained-earnings | 0 | -32.8 | -32.8 | -32.8 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | -2.7 | 0 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 30 | 32.7 | 29.7 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | -0.1 | -0.1 | -0.1 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 0 | -0.1 | -0.1 | -0.1 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-debt | 0 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.net-debt | 0 | 0.1 | 0.1 | 0.1 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0 | 0.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.free-cash-flow | 0 | 0 | 0 | 0 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.cost-and-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.income-before-tax | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.net-income | 0 | 0 | 0 | 0 |
Často kladené otázky
Čo je Lotus Pharmaceuticals, Inc. (LTUS) celkové aktíva?
Lotus Pharmaceuticals, Inc. (LTUS) celkové aktíva sú 5681.000.
Aký je ročný obrat podniku?
Ročné príjmy sú N/A.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.000.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je -0.000.
Aká je čistá zisková marža podniku?
Čistá zisková marža je 0.000.
Aké sú celkové výnosy podniku?
Celkové príjmy sú 0.000.
Aká je Lotus Pharmaceuticals, Inc. (LTUS) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je -18812.000.
Aký je celkový dlh firmy?
Celkový dlh je 116683.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 18812.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 0.000.